Praxis Precision Medicines is a clinical-stage company developing drugs for epilepsy and movement disorders; relutrigine and ulixacaltamide are under FDA review and none are approved.
Praxis's case rests on two drugs under FDA review: relutrigine for SCN2A and SCN8A developmental and epileptic encephalopathies, with a December 27, 2026 PDUFA date, and ulixacaltamide for essential tremor. Ulixacaltamide's PDUFA date is January 29, 2027, and at both mid-cycle meetings FDA identified no major safety or efficacy concerns. Vormatrigine's POWER1 epilepsy trial missed in June, and cash of about $1.4 billion should last into 2028.
Thesis checklist
0 risks need attention
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Next decision point
Tests: FDA approves relutrigine for SCN2A and SCN8A encephalopathies
Does FDA approve relutrigine as the first therapy for SCN2A and SCN8A encephalopathies?
Strong, inconclusive and weak outcomes
What to look for in the result and how each would move the checklist
Price and material events
Select an event marker to read the update below. Marker colors show Thesis status.
FDA decisions on relutrigine (Dec 27) and ulixacaltamide (Jan 29) approach after clean mid-cycle reviews; vormatrigine restarts after POWER1 missed
Relutrigine's September 2026 FDA decision on the first-ever therapy for SCN2A/SCN8A DEE is the single event that validates or resets Praxis's commercial transition
Relutrigine's FDA decision for SCN2A/SCN8A DEE is the pivotal test of Praxis's precision epilepsy platform, with ulixacaltamide and vormatrigine providing breadth but not replacing it as the core value driver
Relutrigine's Sept 2026 FDA decision for SCN2A/SCN8A DEE defines whether Praxis becomes a rare epilepsy franchise or a pipeline story reset by vormatrigine's failure
About this history: every entry shows when the Thesis moved and what it said. The reasoning behind each move (the evidence, the analysis and the source filing) and the earnings write-ups are part of a subscription.
Dates, trials and completed outcomes are open to everyone. What each upcoming milestone hinges on is part of a subscription.
Drug pages: Relutrigine, Ulixacaltamide
Disease areas: Neurology and pain, Psychiatric disorders
Catalyst calendar · Upcoming FDA decisions · Thesis changes
Competitive landscape
10 peers tracked
Cash: Market-data provider estimate; measurement period unavailable.
Debt: Market-data provider estimate; a complete comparable filing balance is unavailable.
Quarterly burn: Estimated from trailing free cash flow; measurement period unavailable.
Net cash and estimated runway require verified matching measurement periods. Missing debt components are not assumed to be zero.
Runway: No underlying guidance available.